Q&A: Do Competing Cannabis Interests Repackage Opioid Research?

A recent cannabis and opioid study highlighted that “corporate actors” with “deep pockets have substantial ability to promote congenial results, as suffering people are desperate for effective solutions.”

Q&A
United States

As Congress Considers Cannabis, Regulators and Lawmakers Convene on Key Issues

A cannabis regulation panel brought together federal lawmakers and regulators, who focused on impairment, science, and efforts at the federal level to change cannabis policy.